Disseminated tumour cells from the bone marrow of early breast cancer patients : Results from an international pooled analysis
| Autor: | Jean-Yves Pierga, Mireia Margeli, Florin Andrei Taran, Tanja Fehm, Vincent P. Walter, Birgitt Schoenfisch, Florian Schuetz, Klaus Pantel, Oliver Hoffmann, Sabine Kasimir-Bauer, Markus Wallwiener, Wolfgang Janni, Gerhard Gebauer, Nadia Harbeck, Lisa Rydén, Alexandra von Au, Christoph Klein, Andreas D. Hartkopf, Sara Y. Brucker, Brigitte Rack, Mårten Fernö, Katherine N. Weilbaecher, Matthias W. Beckmann, Christoph Domschke, François-Clément Bidard, Elin Borgen, Markus Hahn, Julia Kathrin Jueckstock, Bjørn Naume, Peter A. Fasching, Diethelm Wallwiener, Montserrat Solá, Natalia Krawczyk, Minh Hanh Ta, Rebecca Aft, Ann Kathrin Bittner, A. Kurt |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Adult
Oncology Cancer Research medicine.medical_specialty Receptor ErbB-2 Medizin Breast Neoplasms Disease Metastasis Disseminated tumour cells Young Adult Bone Marrow Internal medicine Progesterone receptor medicine Tumour staging Humans Bone marrow Aged Proportional Hazards Models Early breast cancer Aged 80 and over Proportional hazards model business.industry Micrometastasis Middle Aged Prognosis medicine.disease Micrometastases medicine.anatomical_structure Female business Cancer dormancy |
| Zdroj: | European Journal of Cancer r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol instname |
| ISSN: | 0959-8049 |
| Popis: | Purpose: Presence of disseminated tumour cells (DTCs) in the bone marrow (BM) has been described as a surrogate of residual disease in patients with early breast cancer (EBC). PADDY (Pooled Analysis of DTC Detection in Early Breast Cancer) is a large international analysis of pooled data that aimed to assess the prognostic impact of DTCs in patients with EBC. Experimental design: Individual patient data were collected from 11 centres. Patients with EBC and available follow-up data in whom BM sampling was performed at the time of primary diagnosis before receiving any anticancer treatment were eligible. DTCs were identified by antibody staining against epithelial cytokeratins. Multivariate Cox regression was used to compare the survival of DTC-positive versus DTC-negative patients. Results: In total, 10,307 patients were included. Of these, 2814 (27.3%) were DTC-positive. DTC detection was associated with higher tumour grade, larger tumour size, nodal positivity, oestrogen receptor and progesterone receptor negativity, and HER2 positivity (all p < 0.001). Multivariate analyses showed that DTC detection was an independent prognostic marker for overall survival, disease-free survival and distant disease-free survival with hazard ratios (HR) and 95% confidence intervals (CI) of 1.23 (95% CI: 1.06-1.43, p = 0.006), 1.30 (95% CI: 1.12 e1.52, p < 0.001) and 1.30 (95% CI: 1.08-1.56, p = 0.006), respectively. There was no association between locoregional relapse-free survival and DTC detection (HR 1.21; 95% CI 0.68-2.16; p = 0.512). Conclusions: DTCs in the BM represent an independent prognostic marker in patients with EBC. The heterogeneous metastasis-initiating potential of DTCs is consistent with the concept of cancer dormancy. (C) 2021 Elsevier Ltd. All rights reserved. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect